Replies to post #231094 on Biotech Values

[miljenko]

<To my knowledge, VIR’s is the only HBV program planning to incorporate peg-IFN (in the phase-2 trial). Fans of JNJ/ARWR's program claim VIR's use of peg-IFN is a sign of weakness. Do you concur?>

JNJ is combining 3989 with capsid assembly inhibitor JNJ-56136379, and with Entecavir/Tenofovir...so is their siRNA *weak* on its own as well? Or, is it about cure, and not viral suppression only.
Adding PEG-IFN is logical, they may as well use Entecavir/Tenofovir combination. From that, it is not weakness, they have no other choice.